BioSpecifics Technologies Corp is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products and clinical research.
BioSpecifics Technologies Corp. announced, “Chien-801 was a pilot study conducted for the purpose of evaluating the use of purified collagenase for the non-surgical treatment of lipoma in six dogs. The study evaluated the appropriate dosage and frequency of injections necessary to significantly reduce the size of the lipoma.” Read the Full article.
BioSpecifics Technologies Corp. is a biopharmaceutical company, which engages in development of an injectable collagenase for multiple indications. Its product XIAFLEX is an injectable collagenase enzyme, which is used for the treatment of Dupuytren’s contracture in adults with a palpable cord in the palm. The company was founded in 1990 and is headquartered in Lynbrook, NY. [Source: MarketWatch]